Clinical trial
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin…
NCT00441168 · Janssen-Cilag International NV, Industry · Terminated
Key facts
| NCT number | NCT00441168 |
|---|---|
| Title | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma |
| Official title | A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade When Added to Adriamycin-Dexamethasone Treatment Versus Vincristine-Adriamycin-Dexamethasone Standard Treatment in Subjects With Multiple Myeloma Who Are Refractory to or Have Relapsed… |
| Lead sponsor | Janssen-Cilag International NV, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | adriamycin, bortezomib, dexamethasone, vincristine |
| Enrollment | 30 |
| Start date | Dec 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Feb 28, 2007 |
| Last update posted | Mar 21, 2014 |
| Countries | Croatia, Germany, Hungary, Lithuania, Poland, Russia, Turkey (Türkiye) |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: